<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451071</url>
  </required_header>
  <id_info>
    <org_study_id>000518236</org_study_id>
    <nct_id>NCT03451071</nct_id>
  </id_info>
  <brief_title>Postpartum HPV Vaccination</brief_title>
  <official_title>Postpartum HPV Vaccination: Acceptability, Uptake and Immunogenicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human papillomavirus (HPV)-related cancers are on the rise in the United States. Furthermore,&#xD;
      greater than 90% of cervical cancer cases are attributable to HPV, and cervical cancer&#xD;
      disproportionately affects women of color in both incidence and mortality. Due to low HPV&#xD;
      vaccine uptake in the US, innovative approaches to vaccinating vulnerable populations are&#xD;
      necessary in order to maximize the cancer prevention potential of this vaccine. The&#xD;
      puerperium is a time period when women are engaged in the healthcare system and have almost&#xD;
      universal access to affordable health care. Two prior studies have shown that postpartum HPV&#xD;
      vaccination is acceptable to patients, and high rates of vaccination were achieved in these&#xD;
      primarily Hispanic populations. However, data show that the immune response in young women is&#xD;
      less robust than in adolescents, and no studies have examined immunogenicity in postpartum&#xD;
      women specifically. We propose an HPV vaccination pilot study in women who receive postpartum&#xD;
      care at University of Alabama at Birmingham (UAB) hospital. We will examine the&#xD;
      acceptability, uptake and immunogenicity of the vaccine in the postpartum setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2019</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Indication of Willingness to Accept the Vaccine Based on Survey</measure>
    <time_frame>1 day (at the time of initial recruitment /survey)</time_frame>
    <description>This was established using a survey to indicate willingness to receive vaccine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uptake of the Vaccine Doses</measure>
    <time_frame>at baseline</time_frame>
    <description>Those that actually received the vaccine and each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uptake of the Vaccine Doses</measure>
    <time_frame>at 3 months</time_frame>
    <description>Those that actually received the vaccine and each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uptake of the Vaccine Doses</measure>
    <time_frame>at 6 months</time_frame>
    <description>Those that actually received the vaccine and each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Titers of Vaccine-specific HPV Types</measure>
    <time_frame>baseline and 7 months</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">195</enrollment>
  <condition>HPV-Related Malignancy</condition>
  <arm_group>
    <arm_group_label>Gardasil9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gardasil9</intervention_name>
    <description>Gardasil 9</description>
    <arm_group_label>Gardasil9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  postpartum day 0-4 after vaginal or Cesarean delivery at UAB hospital&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Fetal demise or miscarriage, autoimmune disorder, HIV, Hepatitis B/C, chronic steroid&#xD;
             use, preeclampsia, non-English speaking&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 23, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <results_first_submitted>September 8, 2021</results_first_submitted>
  <results_first_submitted_qc>September 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 4, 2021</results_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Haller Smith</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 24, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT03451071/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>195 women consented to participate in the study. 139 consented to survey only, 56 consented to survey and Gardasil9 vaccine.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gardasil9</title>
          <description>Gardasil9: Gardasil 9</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Vaccine</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Vaccine</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Third Vaccine</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Final Questionnaire and Blood Draw</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gardasil9</title>
          <description>Gardasil9: Gardasil 9</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.9" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Indication of Willingness to Accept the Vaccine Based on Survey</title>
        <description>This was established using a survey to indicate willingness to receive vaccine.</description>
        <time_frame>1 day (at the time of initial recruitment /survey)</time_frame>
        <population>56 patients consented to vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil9</title>
            <description>Gardasil9: Gardasil 9</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Indication of Willingness to Accept the Vaccine Based on Survey</title>
          <description>This was established using a survey to indicate willingness to receive vaccine.</description>
          <population>56 patients consented to vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uptake of the Vaccine Doses</title>
        <description>Those that actually received the vaccine and each time point.</description>
        <time_frame>at baseline</time_frame>
        <population>1 participant consented to vaccine and then subsequently withdrew</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil9</title>
            <description>Gardasil9: Gardasil 9</description>
          </group>
        </group_list>
        <measure>
          <title>Uptake of the Vaccine Doses</title>
          <description>Those that actually received the vaccine and each time point.</description>
          <population>1 participant consented to vaccine and then subsequently withdrew</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uptake of the Vaccine Doses</title>
        <description>Those that actually received the vaccine and each time point.</description>
        <time_frame>at 3 months</time_frame>
        <population>1 patient consented to vaccine and then withdrew</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil9</title>
            <description>Gardasil9: Gardasil 9</description>
          </group>
        </group_list>
        <measure>
          <title>Uptake of the Vaccine Doses</title>
          <description>Those that actually received the vaccine and each time point.</description>
          <population>1 patient consented to vaccine and then withdrew</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uptake of the Vaccine Doses</title>
        <description>Those that actually received the vaccine and each time point.</description>
        <time_frame>at 6 months</time_frame>
        <population>36 patients received the 2nd vaccine dose</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil9</title>
            <description>Gardasil9: Gardasil 9</description>
          </group>
        </group_list>
        <measure>
          <title>Uptake of the Vaccine Doses</title>
          <description>Those that actually received the vaccine and each time point.</description>
          <population>36 patients received the 2nd vaccine dose</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Titers of Vaccine-specific HPV Types</title>
        <description>Immunogenicity</description>
        <time_frame>baseline and 7 months</time_frame>
        <population>This data was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil9</title>
            <description>Gardasil9: Gardasil 9</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Titers of Vaccine-specific HPV Types</title>
          <description>Immunogenicity</description>
          <population>This data was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gardasil9</title>
          <description>Gardasil9: Gardasil 9</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Haller Smith</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-934-4986</phone>
      <email>hjsmith@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

